WEE1 and cancer: Currently, there are 58 agents targeting different protein kinases approved by the FDA for the treatment of cancer; 49 of these modulators are indicated for solid tumors including breast, lung, and colon tumors; 5 are indicated for nonsolid tumors, such as leukemias; and 4 (e.g., acalabrutinib, ibrutinib, imatinib, and midostaurin) are indicated for both solid and nonsolid tumors.